Grown Rogue International (GRUSF) Non-Current Debt (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Non-Current Debt of $9.9 million for Q1 2026, up 46.69% year-over-year from $6.8 million in Q1 2025, and down 1.03% quarter-over-quarter from $10.0 million in Q4 2025.
Grown Rogue International (GRUSF) Non-Current Debt (2009 - 2026) Analysis & Trends
Grown Rogue International's Non-Current Debt history runs 17 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 46.69% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (up 46.69% YoY), while the FY2025 annual figure was $10.0 million, up 383.07% from the prior year.
- Non-Current Debt for Q1 2026 stood at $9.9 million, down from $10.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $10424.6 billion in Q3 2025, with the low at $60486.1 in Q4 2023.
- The 5-year median for Non-Current Debt is $1.5 million (2024), against an average of $744.6 billion.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt slumped 83.71% in 2023, then jumped 922180181.77% in 2025.
- Grown Rogue International's Non-Current Debt stood at $631846.4 in 2022, then sank by 90.43% to $60486.1 in 2023, then surged by 3329.07% to $2.1 million in 2024, then surged by 383.07% to $10.0 million in 2025, then retreated by 1.03% to $9.9 million in 2026.
- Business Quant data shows GRUSF's Non-Current Debt at $9.9 million in Q1 2026, $10.0 million in Q4 2025, and $10424.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Grown Rogue International | 113.47 Mn | 101.93 Mn | 5.37 Mn | 9.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.73 Mn |
| Mar 31, 2026 | 9.92 Mn |
| Dec 31, 2025 | 10.02 Mn |
| Sep 30, 2025 | 10,424.63 Bn |
| Jun 30, 2025 | 6.59 Mn |
| Mar 31, 2025 | 6.76 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 60,486.06 |
| Oct 31, 2023 | 102,913.00 |
| Jul 31, 2023 | 149,384.50 |
| Jan 31, 2023 | 339,664.00 |
| Oct 31, 2022 | 631,846.41 |
| Oct 31, 2021 | 1.37 Mn |
| Apr 30, 2021 | 1.17 Mn |
| Jan 31, 2021 | 1.05 Mn |
| Oct 31, 2020 | 753,715.00 |
| Jul 31, 2020 | 485,855.00 |